Pharmaxis tries to dictate terms

This week Pharmaxis achieved a milestone almost unheard of among biotechs in recent times – the successful approval by the European drugs regulator of Bronchitol, its treatment for the debilitating disease, cystic fibrosis. 

Just as amazing is that the drug is un-partnered, meaning a major pharmaceutical company hasn’t assisted in either the clinical development, or the regulatory process.

But as great an achievement as this is, investors always ask, what’s next? ​Sydney Morning Herald – Read more…